Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVS
CUSIPN/A
Phone41-61-324-1111
Debt
Debt-to-Equity Ratio0.30
Current Ratio1.15
Quick Ratio0.89
Price-To-Earnings
Trailing P/E Ratio18.00
Forward P/E Ratio16.70
P/E Growth1.8
Sales & Book Value
Annual Sales$49.11 billion
Price / Sales4.07
Cash Flow$7.5529 per share
Price / Cash11.43
Book Value$32.03 per share
Price / Book2.70
Profitability
EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Net Margins27.06%
Return on Equity16.05%
Return on Assets8.67%
Miscellaneous
Employees125,000
Outstanding Shares2,317,460,000
Market Cap$199.67 billion
Novartis (NYSE:NVS) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How will Novartis' stock buyback program work?
Novartis declared that its board has authorized a share repurchase plan on Saturday, April 8th 2017, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 2.9% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.
How were Novartis' earnings last quarter?
Novartis AG (NYSE:NVS) issued its earnings results on Thursday, October, 18th. The company reported $1.32 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.34 by $0.02. The business earned $12.78 billion during the quarter, compared to analysts' expectations of $12.88 billion. Novartis had a net margin of 27.06% and a return on equity of 16.05%. Novartis's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.29 EPS. View Novartis' Earnings History.
When is Novartis' next earnings date?
What price target have analysts set for NVS?
15 brokers have issued twelve-month price targets for Novartis' shares. Their predictions range from $74.71 to $91.00. On average, they expect Novartis' share price to reach $82.8550 in the next year. This suggests that the stock has a possible downside of 2.8%. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 12 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bayer (BAYRY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
- Mr. Harry Kirsch, Chief Financial Officer (Age 53)
- Mr. Steven Baert, Head of HR (Age 44)
- Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)
- Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 46)
Who are Novartis' major shareholders?
Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.15%), Aperio Group LLC (0.04%), Bristol John W & Co. Inc. NY (0.04%), Bartlett & Co. LLC (0.02%), Douglas Lane & Associates LLC (0.01%) and Park National Corp OH (0.01%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.
Which institutional investors are selling Novartis stock?
NVS stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Park National Corp OH, Scout Investments Inc., Welch & Forbes LLC, World Asset Management Inc, Douglass Winthrop Advisors LLC, Bristol John W & Co. Inc. NY and Advisors Capital Management LLC. View Insider Buying and Selling for Novartis.
Which institutional investors are buying Novartis stock?
NVS stock was acquired by a variety of institutional investors in the last quarter, including Aperio Group LLC, Raymond James Trust N.A., We Are One Seven LLC, First Hawaiian Bank, Fox Run Management L.L.C., Hemenway Trust Co LLC, Gardiner Nancy B and Nisa Investment Advisors LLC. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.
How do I buy shares of Novartis?
Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novartis' stock price today?
One share of NVS stock can currently be purchased for approximately $85.28.
How big of a company is Novartis?
Novartis has a market capitalization of $199.67 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 125,000 workers across the globe.
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]
MarketBeat Community Rating for Novartis (NYSE NVS)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
